Q3 2025 Earnings Call Transcript November 5, 2025 Ocugen, Inc. misses on earnings expectations. Reported EPS is $-0.06596 EPS ...
A photovoltaic retinal implant shows promise as a way to improve vision in patients with advanced age-related macular ...
Conference Call and Webcast Today at 8:30 a.m. ETPhase 2/3 OCU410ST GARDian3 pivotal confirmatory trial is progressing toward ...
The success of the surgery marks a key leap from "feasibility" to "practicality" in China's field of remote high-precision ...
A breakthrough in the field of telemedicine has just been recorded when Chinese doctors successfully performed a subretinal ...
The subretinal mode of injection involves the injection of the vector in the subretinal space between the layer of photoreceptors and the retinal pigment epithelium. Delivery of vectors via the ...
When the FDA approved Spark Therapeutics’ Luxturna in December 2017, gene therapy became a household concept. Chatter about gene therapy curing blindness became hot fodder at dinner tables and ...
CAMBRIDGE, Mass., May 18, 2018 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (NASDAQ:EDIT), a leading genome editing company, today announced results from a pre-clinical study demonstrating that EDIT-101 ...
Majority of patients demonstrated successful efficacy readouts across structural measurements (foveal schisis closure) and had meaningful improvement on visual function measurements including MP, BCVA ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback